Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure

Launched by CENTRE DE RECHERCHE DE L'INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUEBEC · Jun 22, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different types of medications are in preventing blood clots in patients who have recently had a device implanted to close off the left atrial appendage, which is a small pouch in the heart. The trial will compare short-term anticoagulation therapy (which helps prevent blood clots) with antiplatelet therapy (which helps keep platelets from sticking together) over a period of 8 weeks. The goal is to find out which treatment works better in reducing the risk of blood clots, which can lead to serious problems like stroke.

To participate in this study, patients must be at least 18 years old and have successfully undergone the procedure to close the left atrial appendage using an approved device. However, individuals with certain health conditions, such as severe kidney disease or those who have had significant bleeding problems recently, may not be eligible. If you join the trial, you will receive one of the two treatments and be monitored closely for any side effects or complications. This research aims to improve the care and safety of patients undergoing this heart procedure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Successful transcatheter LAAC with any approved device
• • Age≥18 years old
• Exclusion Criteria:
• • Absolute contraindications for anticoagulation therapy
• • Absolute contraindications for antiplatelet therapy
• • End-stage renal disease (CrCl \<15 ml/min)
• • Recent percutaneous revascularization with drug-eluting stents requiring dual antiplatelet therapy
• • Prior intracranial hemorrhage
• • Contraindications for TEE
• • Severe pericardial effusion within the first 24 hrs following LAAC
• • Major/life-threatening bleeding event within the month prior to LAAC
• • Multiple bleeding events (minor or major) within the month prior to LAAC
• • Major/life-threatening bleeding within the first 24 hrs following LAAC